NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or n plus cetuximab (C) in patients (pts) with "quadruple wild-type (WT)" (KRAS/NRAS/BRAF/PIK3CA WT) metastatic colorectal cancer (mCRC) based on HER2 status-Amplified (amp), non-amplified (non-amp), WT, or mutated (mt).

被引：5

作者：

Jacobs, Samuel A.

Lee, James J.

George, Thomas J.

Yothers, Greg

Kolevska, Tatjana

Yost, Kathleen J.

Wade, James Lloyd

Buchschacher, Gary L.

Stella, Philip J.

Shipstone, Asheesh

Pogue-Geile, Katherine L.

Srinivasan, Ashok

Lucas, Peter C.

Allegra, Carmen Joseph

机构：

[1] NSABP Fdn, Pittsburgh, PA USA

[2] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA

[3] Univ Pittsburgh, Pittsburgh, PA USA

[4] NRG Oncol, Gainesville, FL USA

[5] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA

[6] Kaiser Permanente, Mill Valley, CA USA

[7] NSABP Fdn, Grand Rapids, MI USA

[8] Canc Res Consortium West Michigan NCORP, Grand Rapids, MI USA

[9] NSABP Fdn, Decatur, IL USA

[10] Decatur Mem Hosp, Decatur, IL USA

[11] Southern Calif Permenente Med Grp, Los Angeles, CA USA

[12] NSABP Fdn, Ann Arbor, MI USA

[13] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA

[14] NSABP Fdn, Kingsport, TN USA

[15] Wellmont Hlth Syst Hosp, Kingsport, TN USA

[16] NSABP Fdn, Gainesville, FL USA

[17] Univ Florida, Gainesville, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.TPS716

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS716

引用

页数：2

共 9 条

[1] NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
Jacobs, Samuel A.
George, Thomas J.
Kolevska, Tatjana
Wade, James Lloyd
Zera, Richard
Buchschacher, Gary L.
Al Baghdadi, Tareq
Shipstone, Asheesh
Lin, Daniel
Yothers, Greg
Pogue-Geile, Katherine L.
Huggins-Puhalla, Shannon Leigh
Allegra, Carmen Joseph
Wolmark, Norman
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Jacobs, Samuel A.
Lee, James J.
George, Thomas J.
Wade, James L., III
Stella, Philip J.
Wang, Ding
Sama, Ashwin R.
Piette, Fanny
Pogue-Geile, Katherine L.
Kim, Rim S.
Gavin, Patrick G.
Lipchik, Corey
Feng, Huichen
Wang, Ying
Finnigan, Melanie
Kiesel, Brian F.
Beumer, Jan H.
Wolmark, Norman
Lucas, Peter C.
Allegra, Carmen J.
Srinivasan, Ashok
CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1612 - 1622
[3] Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI-GOIM trial
Ciardiello, F.
Martinelli, E.
Cardone, C.
Troiani, T.
Normanno, N.
Pisconti, S.
Bordonaro, R.
Nappi, A.
Giuliani, F.
Biglietto, M.
Barone, C.
Rachiglio, A. M.
Montesarchio, V.
Cinieri, S.
Rizzi, D.
Febbraro, A.
Latiano, T.
Modoni, G.
Colucci, G.
Maiello, E.
ANNALS OF ONCOLOGY, 2017, 28 : 9 - 9
[4] Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI-GOIM trial
Martinelli, E.
Cardone, C.
Troiani, T.
Normanno, N.
Pisconti, S.
Bordonaro, R.
Nappi, A.
Giuliani, F.
Biglietto, M.
Barone, C.
Rachiglio, A. M.
Montesarchio, V.
Cinieri, S.
Rizzi, D.
Febbraro, A.
Latiano, T. P.
Modoni, G.
Colucci, G.
Maiello, E.
Ciardiello, F.
ANNALS OF ONCOLOGY, 2017, 28
[5] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
Personeni, Nicola
Rimassa, Lorenza
Verusio, Claudio
Barni, Sandro
Destro, Annarita
Raschioni, Carlotta
Armenia, Silvia
Floriani, Irene
Gerardi, Chiara
Monteforte, Marta
Villa, Eugenio
Bozzarelli, Silvia
Roncalli, Massimo
Torri, Valter
Labianca, Roberto
Santoro, Armando
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[6] Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
Stintzing, S.
Jung, A.
Rossius, L.
Modest, D. P.
von Weikersthal, L. Fischer
Decker, T.
Moehler, M.
Scheithauer, W.
Kirchner, T.
Heinemann, V.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S8 - S9
[7] Phase II trial of cetuximab (Cmab) plus irinotecan (CPT-11) for chemorefractory Japanese patients with advanced and/or metastatic colorectal cancer (mCRC), to evaluate the efficacy and safety based on KRAS, BRAF, PIK3CA, NRAS, and AKT1 mutation status (T-CORE0801)
Shimodaira, Hideki
Soeda, Hiroshi
Ohori, Hisatsugu
Akiyama, Shoko
Kambe, Mariko
Murakawa, Yasuko
Suzuki, Takao
Kato, Satoshi
Itoh, Jugoh
Watanabe, Mika
Yamaguchi, Takuhiro
Kato, Shunsuke
Ishioka, Chikashi
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[8] NSABP FC-6: Phase II Study to Determine Surgical Conversion Rate in Patients (pts) Receiving Neoadjuvant (NA) mFOLFOX7 Plus Dose-escalating Cetuximab (C) for Unresectable K-RAS Wild-type (WT) Colorectal Cancer with Metastases (mCRC) Confined to the Liver
Wagman, L. D.
Geller, D. A.
Jacobs, S. A.
Petrelli, N. J.
Allegra, C. J.
Buyse, M.
Wolmark, N.
O'Connell, M. J.
ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S13 - S13
[9] Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G
Sugimoto, Naotoshi
Sakai, Daisuke
Tamura, Takao
Hara, Hiroki
Nishina, Tomohiro
Esaki, Taito
Okuda, Hiroyuki
Denda, Tadamichi
Tsuda, Masahiro
Satoh, Taroh
Makiyama, Akitaka
Yamazaki, Kentaro
Kuramochi, Hidekazu
Hosokawa, Ayumu
Tsuda, Takashi
Taniguchi, Hiroya
Kishimoto, Junji
Boku, Narikazu
Hyodo, Ichinosuke
Muro, Kei
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)

← 1 →